JP2015520229A - 神経心理学的障害の治療用の組成物および方法 - Google Patents

神経心理学的障害の治療用の組成物および方法 Download PDF

Info

Publication number
JP2015520229A
JP2015520229A JP2015518386A JP2015518386A JP2015520229A JP 2015520229 A JP2015520229 A JP 2015520229A JP 2015518386 A JP2015518386 A JP 2015518386A JP 2015518386 A JP2015518386 A JP 2015518386A JP 2015520229 A JP2015520229 A JP 2015520229A
Authority
JP
Japan
Prior art keywords
administered
amount
composition
day
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015518386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520229A5 (enExample
Inventor
ジョン・ディー・カイザー
Original Assignee
ケー−パックス・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケー−パックス・ファーマシューティカルズ・インコーポレイテッド filed Critical ケー−パックス・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2015520229A publication Critical patent/JP2015520229A/ja
Publication of JP2015520229A5 publication Critical patent/JP2015520229A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015518386A 2012-06-22 2012-11-30 神経心理学的障害の治療用の組成物および方法 Pending JP2015520229A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/530,673 2012-06-22
US13/530,673 US9040082B2 (en) 2011-06-24 2012-06-22 Compositions and methods for treatment of chronic fatigue
PCT/US2012/067347 WO2013191724A1 (en) 2012-06-22 2012-11-30 Compositions and methods for treatment of neuropsychological deficits

Publications (2)

Publication Number Publication Date
JP2015520229A true JP2015520229A (ja) 2015-07-16
JP2015520229A5 JP2015520229A5 (enExample) 2015-12-17

Family

ID=49769962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015518386A Pending JP2015520229A (ja) 2012-06-22 2012-11-30 神経心理学的障害の治療用の組成物および方法

Country Status (6)

Country Link
US (2) US9040082B2 (enExample)
EP (1) EP2879495A4 (enExample)
JP (1) JP2015520229A (enExample)
AU (1) AU2012382949A1 (enExample)
CA (1) CA2849968A1 (enExample)
WO (1) WO2013191724A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9040082B2 (en) * 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
JP5973073B2 (ja) 2013-11-08 2016-08-23 イーライ リリー アンド カンパニー アトモキセチン溶液
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
WO2020176807A1 (en) 2019-02-27 2020-09-03 Vanderbilt University Methods of treating trigeminal nerve pain
US20250049737A1 (en) * 2021-07-08 2025-02-13 Nls Pharmaceutics Ag Lauflumide and derivatives thereof for treating chronic fatigue syndrome and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04211614A (ja) * 1990-03-06 1992-08-03 Interneuron Pharmaceut Inc 能力増強方法および組成物
US6845777B2 (en) * 2001-10-22 2005-01-25 Ivo E. Pera Composition to reduce or quit smoking addiction
WO2006112283A1 (ja) * 2005-04-13 2006-10-26 Riken Vitamin Co., Ltd. 抗疲労剤
US20060257502A1 (en) * 2005-05-11 2006-11-16 Jiankang Liu A combination of mitochondrial nutrients for relieving stress, preventing and improving stress-related disorders
JP2007502863A (ja) * 2003-05-23 2007-02-15 コグニション ファーマシューティカルズ エルエルシー 認知障害の治療および認知改善の方法
JP2007153816A (ja) * 2005-12-06 2007-06-21 Taisho Pharmaceut Co Ltd 疲労改善剤組成物
JP2012024555A (ja) * 2010-06-24 2012-02-09 Institute Of Physical & Chemical Research 疲労のバイオマーカーおよびその利用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542123A (en) 1982-01-11 1985-09-17 Massachusetts Institute Of Technology Composition and method for increasing brain tyrosine levels
US6451341B1 (en) 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US5292538A (en) 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5948443A (en) 1996-02-23 1999-09-07 Medical Doctor's Research Institute, Inc. Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease
US5895652A (en) 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
JP2001511153A (ja) 1997-02-04 2001-08-07 ブイ． コスバブ，ジョン 血管変性性疾患の予防および処置のための組成物および方法
IT1291113B1 (it) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US5916912A (en) 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress
US6048846A (en) 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US6191162B1 (en) 1998-05-28 2001-02-20 Medical Research Institute Method of reducing serum glucose levels
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
US20030206895A1 (en) 1998-11-13 2003-11-06 Sigma-Tau Healthscience S.P.A. Antioxidant composition comprising propionyl L-carnitine and a flavonoid against throm-bosis and atherosclerosis
EP1175158A1 (en) 1999-05-07 2002-01-30 Trustees Of Tufts College Immune stimulating dietary supplement and methods of use thereof
CA2377414A1 (en) 1999-06-15 2000-12-21 John D. Potter Nutrient formulations for disease reduction, and related treatment and component screening methods
US6103756A (en) 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6479069B1 (en) 1999-09-23 2002-11-12 Juvenon, Inc. Nutritional supplement for increased energy and stamina
AU8003800A (en) * 1999-10-08 2001-04-23 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
US20020155163A1 (en) 1999-12-27 2002-10-24 Samuel D. Benjamin Integrated multi-vitamin and mineral combination
US6458384B2 (en) 2000-02-23 2002-10-01 Impetus Ag Pharmaceutical with predetermined activity profile
US6579544B1 (en) 2000-05-31 2003-06-17 Nutriex, L.L.C. Method for supplementing the diet
US6423349B1 (en) 2000-08-24 2002-07-23 Baxter International, Inc. Therapeutic nutrient composition for pre and post elective surgery
US20070117869A1 (en) 2000-11-01 2007-05-24 Cognition Pharmaceuticals Llc Methods for treating coginitive impairment and improving cognition
WO2005000203A2 (en) 2001-10-31 2005-01-06 Sention, Inc. Methods for treating cognitive impairment and improving cognition
US6733797B1 (en) 2000-11-15 2004-05-11 William K. Summers Neuroceutical for improving memory and cognitive abilities
US20020176900A1 (en) 2000-11-22 2002-11-28 Inna Yegorova Compositions and methods for promoting a healthy cardiovascular system and enhancing blood flow
US6300377B1 (en) 2001-02-22 2001-10-09 Raj K. Chopra Coenzyme Q products exhibiting high dissolution qualities
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
WO2002087593A1 (en) 2001-04-25 2002-11-07 Cobalz Limited A method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method
US20020165281A1 (en) * 2001-04-26 2002-11-07 Assa Weinberg Treatment of anoxic encephalophathy by administration of N-acetylcystein
DE60232522D1 (de) 2001-07-11 2009-07-16 Cns Response Inc Verfahren zur vorhersage der behandlungsresultate
US6541043B2 (en) 2001-08-28 2003-04-01 Dexgen Pharmaceuticals, Inc. Method and synergistic composition for treating attention deficit/hyperactivity disorder
US20030049272A1 (en) 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
WO2003028747A1 (en) 2001-10-04 2003-04-10 Harris Dennis H Ingestible nerve and circulatory nutritional formulation
GB2381451A (en) 2001-11-01 2003-05-07 New Technology Res Ltd Pharmaco-dietary preparation having nutrition-supplementing and nutrition-enhancing effect
US20040077556A1 (en) 2002-04-22 2004-04-22 Robert Chinery Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals
US7585523B2 (en) 2002-08-27 2009-09-08 Targeted Medical Pharma Composition and method to augment and sustain neurotransmitter production
US7968125B2 (en) 2003-04-08 2011-06-28 Janeel Henderson Energy generating composition
US20070237834A1 (en) 2003-04-18 2007-10-11 Bioderm Research Zinc Zeolite for the Treatment for Diaper Rash (Diaper Dermatitis)
US20050058672A1 (en) 2003-09-14 2005-03-17 Bioderm Research Baby Care Skin Protectant Compositions for Diaper Rash
US8211873B2 (en) 2003-08-29 2012-07-03 Island Kinetics, Inc. Antiaging chirally-correct mitoprotectant amino acid and peptide complexes
CA2550625C (en) 2003-12-31 2013-05-28 Integrative Health Consulting, Inc. Nutrient compositions and methods for enhanced effectiveness of the immune system
PL1797109T3 (pl) 2004-09-09 2016-11-30 Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania
MX2007006324A (es) 2004-11-29 2007-10-17 Aloecorp Inc Deshidratacion de combinaciones de alimentos.
US7250181B2 (en) 2005-01-19 2007-07-31 Natreon, Inc. Polyherbal compositions and methods for treating viral infections
US7776915B2 (en) 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
US7645742B2 (en) 2005-06-22 2010-01-12 Advocare International, L.P. Composition for enhancing cellular energy
US7893070B2 (en) 2005-08-15 2011-02-22 Provimi Holding B.V. Method of treating parturient placental mammals in order to reduce maternal and/or uterine exhaustion
US7976879B2 (en) 2005-11-04 2011-07-12 Roizen Michael F Nutritional supplement product to suppress age-related decline in cognitive capacity and other aging functions
MX2008011639A (es) 2006-03-13 2008-09-23 Hershey Co Composiciones de infusion de cacao y bebidas funcionales de cacao elaboradas a partir de las mismas.
US7972633B2 (en) 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
EP2433654A3 (en) 2007-02-08 2013-05-15 Kempharm, Inc. Citrulline and homocitrulline prodrugs of amphetamines and processes for making and using the same
US8187647B2 (en) 2008-06-13 2012-05-29 BioClinical Development, Inc. Edible energy composition
WO2009098697A1 (en) 2008-02-08 2009-08-13 Dexxon Ltd. Modafinil and sildenafil dosage forms
EP2259782A4 (en) 2008-03-03 2013-01-23 Nad Life Pty Ltd PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHOD FOR THEIR USE IN THE TREATMENT OF CELL DISEASES
US20090325999A1 (en) 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
US8642095B2 (en) 2008-09-30 2014-02-04 Visalus Holdings, Llc Dietary composition and method of using the same
CA2785056A1 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
US9872850B2 (en) 2010-12-23 2018-01-23 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04211614A (ja) * 1990-03-06 1992-08-03 Interneuron Pharmaceut Inc 能力増強方法および組成物
US6845777B2 (en) * 2001-10-22 2005-01-25 Ivo E. Pera Composition to reduce or quit smoking addiction
JP2007502863A (ja) * 2003-05-23 2007-02-15 コグニション ファーマシューティカルズ エルエルシー 認知障害の治療および認知改善の方法
WO2006112283A1 (ja) * 2005-04-13 2006-10-26 Riken Vitamin Co., Ltd. 抗疲労剤
US20060257502A1 (en) * 2005-05-11 2006-11-16 Jiankang Liu A combination of mitochondrial nutrients for relieving stress, preventing and improving stress-related disorders
JP2007153816A (ja) * 2005-12-06 2007-06-21 Taisho Pharmaceut Co Ltd 疲労改善剤組成物
JP2012024555A (ja) * 2010-06-24 2012-02-09 Institute Of Physical & Chemical Research 疲労のバイオマーカーおよびその利用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE AMERICAN JOURNAL OF MEDICINE, vol. 119, JPN6016035248, 2006, pages 167 - 23, ISSN: 0003399475 *

Also Published As

Publication number Publication date
US20120328695A1 (en) 2012-12-27
EP2879495A1 (en) 2015-06-10
WO2013191724A1 (en) 2013-12-27
US20150250761A1 (en) 2015-09-10
EP2879495A4 (en) 2016-03-09
AU2012382949A8 (en) 2014-09-04
AU2012382949A1 (en) 2014-01-30
US9040082B2 (en) 2015-05-26
CA2849968A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
JP6574809B2 (ja) 慢性疲労の治療用の組成物および方法
KR102795284B1 (ko) 베타-히드록시부티레이트 및 부탄디올의 s-거울상이성질체 및 이의 사용 방법
US20200347413A1 (en) Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
JP2015520229A (ja) 神経心理学的障害の治療用の組成物および方法
Farah The role of L-methylfolate in depressive disorders
US20150238518A1 (en) Compositions and methods for treatment of neuropsychological deficits
US20160008300A1 (en) Compositions and Methods for Nutritional Supplementation
US20160228425A1 (en) Compositions and methods for treatment of gulf war illness
CN1454090A (zh) 用于提高心血管功能的组合物和方法
KR20010022008A (ko) 주의력-결핍/과잉행동 장애 치료를 위한 알카노일카르니틴 유도체의 용도
US20080114067A1 (en) Composition for Recovery From or Prevention of Central Nervous System Fatigue
US20250248959A1 (en) Compositions and methods for treating neurodevelopmental disorders
KR20150060954A (ko) 아포에쿼린-함유 조성물을 기반으로 하는 다발성 경화증의 증상을 완화시키는 방법
BE1025418B1 (nl) Voedingssupplement en toepassingen
US20100240588A1 (en) Compound for use in the treatment of peripheral neuropathies
CN120919102A (zh) 蛋氨酸在制备用于改善精神分裂症社交障碍的药物或组合物中的用途
ES2246736B1 (es) &#34;composicion farmaceutica que comprende un principio activo antivirico y usos correspondientes&#34;.
Rostain Guanfacine extended release in the treatment of attention-deficit/hyperactivity disorder
JPH0449235A (ja) 痴呆治療剤
EA022732B1 (ru) Фармацевтическая композиция и набор для профилактики и лечения нарушений, связанных с избыточным весом или ожирением, их применение и способ профилактики и лечения нарушений, связанных с избыточным весом или ожирением

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170509